Grant of Share Options to Directors, PDMRs and Employees and Grant of Restricted Stock Units to Non-Executive Directors
26 October 2017 - 12:00AM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, announces
that the following options over new ordinary shares of 1 penny
nominal value (‘Ordinary Shares’) were granted on 24 October 2017
to Directors, PDMRs and employees in line with the Company’s Long
Term Incentive Plan. The Company has also made a grant of
restricted stock units (‘RSUs’) to the Non-Executive Directors
under the Company’s 2017 Remuneration Policy. Details of both
grants are summarised below.
Grant of Share Options
Director/PDMR |
Position |
Options Awarded |
Total Options Held |
Glyn Edwards |
Chief Executive Officer |
198,776 |
2,994,310 |
Erik Ostrowski |
Chief Financial Officer |
98,495 |
1,216,557 |
These options have an exercise price of 180
pence per share and will vest in full on 24 October 2020 subject to
achievement of performance conditions pertaining to corporate and
programme development milestones.
Options over 493,727 Ordinary Shares were
granted to other employees of the Company. These options have an
exercise price of 180 pence per share. They will vest in nine equal
tranches on a quarterly basis from 24 October 2018 and will vest in
full on 24 October 2020.
Award of Restricted Stock Units
Director |
Position |
RSU’s Awarded |
Total RSUs Held |
Frank Armstrong |
Non-Exective Chairman |
41,666 |
82,762 |
Barry Price |
Non-Executive Director |
19,444 |
38,623 |
Stephen Davies |
Non-Executive Director |
19,444 |
38,623 |
Leopoldo Zambeletti |
Non-Executive Director |
19,444 |
38,623 |
Valerie Andrews |
Non-Executive Director |
19,444 |
38,623 |
Dave Wurzer |
Non-Executive Director |
19,444 |
38,623 |
Each RSU entitles the holder to subscribe for an
Ordinary Share at a subscription price of 1 penny per Ordinary
Share. The RSUs have a vesting period of one year and no
performance conditions. The RSU programme is part of the 2017
Remuneration Policy. The RSUs granted will vest on 24 October
2018.
The notifications set out below are provided in
accordance with the requirements of the EU Market Abuse
Regulation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit Glyn Edwards / Richard Pye
(UK office)Erik Ostrowski / Michelle Avery (US office) |
Tel:
+44 (0)1235 443 951 +1 617 225 4455 |
|
|
Cairn Financial Advisers LLP(Nominated
Adviser)Liam Murray / Tony Rawlinson |
Tel:
+44 (0)20 7213 0880 |
|
|
N+1 Singer (Broker)Aubrey Powell / Lauren
Kettle |
Tel: +44 (0)20 7496 3000 |
|
|
MacDougall Biomedical Communications(US media
contact)Karen Sharma |
Tel:
+1 781 235 3060ksharma@macbiocom.com |
|
|
Consilium
Strategic Communications (Financial public relations,
UK)Mary-Jane Elliott / Jessica Hodgson / Philippa Gardner / Rosie
Philips |
Tel: +44 (0)20 3709
5700 summit@consilium-comms.com |
|
|
Notification of a Transaction pursuant to Article 19(1)
of Regulation (EU) No. 596/2014
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name |
Mr Glyn Edwards |
2 |
Reason for the notification |
a) |
Position / status |
Chief Executive Officer |
b) |
Initial notification / Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Summit Therapeutics plc |
b) |
LEI |
213800NRW8AOMYMTBD89 |
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 1 penny each |
|
|
Identification code |
GB00BN40HZ01 |
b) |
Nature of the transactions |
Grant of share options |
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
180 pence per share (exercise price) |
198,776 |
|
d) |
Aggregated information |
|
- Aggregated volume |
N/A |
- Price |
|
e) |
Date of the transaction |
24 October 2017 |
f) |
Place of the transaction |
Outside a trading venue |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name |
Mr Erik Ostrowski |
2 |
Reason for the notification |
a) |
Position / status |
Chief Financial Officer |
b) |
Initial notification / Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Summit Therapeutics plc |
b) |
LEI |
213800NRW8AOMYMTBD89 |
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 1 penny each |
|
|
Identification code |
GB00BN40HZ01 |
b) |
Nature of the transactions |
Grant of share options |
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
180 pence per share (exercise price) |
98,495 |
|
d) |
Aggregated information |
|
- Aggregated volume |
N/A |
- Price |
|
e) |
Date of the transaction |
24 October 2017 |
f) |
Place of the transaction |
Outside a trading venue |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name |
Dr Frank Armstrong |
2 |
Reason for the notification |
a) |
Position / status |
Non-Executive Chairman |
b) |
Initial notification / Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Summit Therapeutics plc |
b) |
LEI |
213800NRW8AOMYMTBD89 |
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 1 penny each |
|
|
Identification code |
GB00BN40HZ01 |
b) |
Nature of the transactions |
Grant of restricted stock units |
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
1 penny per share (subscription price) |
41,666 |
|
d) |
Aggregated information |
|
- Aggregated volume |
N/A |
- Price |
|
e) |
Date of the transaction |
24 October 2017 |
f) |
Place of the transaction |
Outside a trading venue |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name |
Dr Barry Price |
2 |
Reason for the notification |
a) |
Position / status |
Non-Executive Director |
b) |
Initial notification / Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Summit Therapeutics plc |
b) |
LEI |
213800NRW8AOMYMTBD89 |
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 1 penny each |
|
|
Identification code |
GB00BN40HZ01 |
b) |
Nature of the transactions |
Grant of restricted stock units |
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
1 penny per share (subscription price) |
19,444 |
|
d) |
Aggregated information |
|
- Aggregated volume |
N/A |
- Price |
|
e) |
Date of the transaction |
24 October 2017 |
f) |
Place of the transaction |
Outside a trading venue |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name |
Professor Stephen Davies |
2 |
Reason for the notification |
a) |
Position / status |
Non-Executive Director |
b) |
Initial notification / Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Summit Therapeutics plc |
b) |
LEI |
213800NRW8AOMYMTBD89 |
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 1 penny each |
|
|
Identification code |
GB00BN40HZ01 |
b) |
Nature of the transactions |
Grant of restricted stock units |
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
1 penny per share (subscription price) |
19,444 |
|
d) |
Aggregated information |
|
- Aggregated volume |
N/A |
- Price |
|
e) |
Date of the transaction |
24 October 2017 |
f) |
Place of the transaction |
Outside a trading venue |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name |
Mr Leopoldo Zambeletti |
2 |
Reason for the notification |
a) |
Position / status |
Non-Executive Director |
b) |
Initial notification / Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Summit Therapeutics plc |
b) |
LEI |
213800NRW8AOMYMTBD89 |
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 1 penny each |
|
|
Identification code |
GB00BN40HZ01 |
b) |
Nature of the transactions |
Grant of restricted stock units |
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
1 penny per share (subscription price) |
19,444 |
|
d) |
Aggregated information |
|
- Aggregated volume |
N/A |
- Price |
|
e) |
Date of the transaction |
24 October 2017 |
f) |
Place of the transaction |
Outside a trading venue |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name |
Ms Valerie Andrews |
2 |
Reason for the notification |
a) |
Position / status |
Non-Executive Director |
b) |
Initial notification / Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Summit Therapeutics plc |
b) |
LEI |
213800NRW8AOMYMTBD89 |
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 1 penny each |
|
|
Identification code |
GB00BN40HZ01 |
b) |
Nature of the transactions |
Grant of restricted stock units |
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
1 penny per share (subscription price) |
19,444 |
|
d) |
Aggregated information |
|
- Aggregated volume |
N/A |
- Price |
|
e) |
Date of the transaction |
24 October 2017 |
f) |
Place of the transaction |
Outside a trading venue |
1 |
Details of the person discharging managerial
responsibilities/person closely associated |
a) |
Name |
Mr Dave Wurzer |
2 |
Reason for the notification |
a) |
Position / status |
Non-Executive Director |
b) |
Initial notification / Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor |
a) |
Name |
Summit Therapeutics plc |
b) |
LEI |
213800NRW8AOMYMTBD89 |
4 |
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted |
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 1 penny each |
|
|
Identification code |
GB00BN40HZ01 |
b) |
Nature of the transactions |
Grant of restricted stock units |
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
1 penny per share (subscription price) |
19,444 |
|
d) |
Aggregated information |
|
- Aggregated volume |
N/A |
- Price |
|
e) |
Date of the transaction |
24 October 2017 |
f) |
Place of the transaction |
Outside a trading venue |
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From May 2023 to May 2024